AU2019250507B2 - Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase - Google Patents

Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase Download PDF

Info

Publication number
AU2019250507B2
AU2019250507B2 AU2019250507A AU2019250507A AU2019250507B2 AU 2019250507 B2 AU2019250507 B2 AU 2019250507B2 AU 2019250507 A AU2019250507 A AU 2019250507A AU 2019250507 A AU2019250507 A AU 2019250507A AU 2019250507 B2 AU2019250507 B2 AU 2019250507B2
Authority
AU
Australia
Prior art keywords
compound
absent
cancer
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019250507A
Other languages
English (en)
Other versions
AU2019250507A1 (en
Inventor
Jan Eickhoff
Yeejin JEON
Jaeseung Kim
Kiyean NAM
Dongsik Park
Mooyoung SEO
Donghoon Yu
Gunther Zischinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Discovery Center GmbH
Qurient Co Ltd
Original Assignee
Lead Discovery Center GmbH
Qurient Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center GmbH, Qurient Co Ltd filed Critical Lead Discovery Center GmbH
Publication of AU2019250507A1 publication Critical patent/AU2019250507A1/en
Application granted granted Critical
Publication of AU2019250507B2 publication Critical patent/AU2019250507B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019250507A 2018-04-11 2019-04-11 Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase Active AU2019250507B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656070P 2018-04-11 2018-04-11
US62/656,070 2018-04-11
PCT/EP2019/059302 WO2019197549A1 (en) 2018-04-11 2019-04-11 Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase

Publications (2)

Publication Number Publication Date
AU2019250507A1 AU2019250507A1 (en) 2020-10-22
AU2019250507B2 true AU2019250507B2 (en) 2023-09-28

Family

ID=66334385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019250507A Active AU2019250507B2 (en) 2018-04-11 2019-04-11 Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase

Country Status (14)

Country Link
US (1) US11945822B2 (enExample)
EP (1) EP3774810A1 (enExample)
JP (2) JP7772501B2 (enExample)
KR (1) KR102966455B1 (enExample)
CN (1) CN112313235A (enExample)
AU (1) AU2019250507B2 (enExample)
BR (1) BR112020020768A2 (enExample)
CA (1) CA3095880A1 (enExample)
IL (1) IL277770B2 (enExample)
MX (1) MX2020010675A (enExample)
MY (1) MY199647A (enExample)
PH (1) PH12020551639A1 (enExample)
SG (1) SG11202009724YA (enExample)
WO (1) WO2019197549A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220144841A1 (en) * 2019-03-13 2022-05-12 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
EP3725788A1 (en) * 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
US20230115907A1 (en) 2019-12-20 2023-04-13 Evopoint Biosciences Co., Ltd. Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and use thereof
CA3174507A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
CN112079781B (zh) * 2020-09-30 2022-11-22 苏州康润医药有限公司 5-溴-1-甲基-1h-吡唑-3-胺的合成方法
EP4255909A1 (en) 2020-12-02 2023-10-11 Qurient Co. Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN114195710A (zh) * 2021-12-20 2022-03-18 上海彩迩文生化科技有限公司 一种喹啉类胺甲基化合物的制备方法
WO2024151112A1 (ko) * 2023-01-11 2024-07-18 주식회사 티움바이오 사이클린 의존성 키나아제 9 저해제로서의 피라졸로피리미딘 유도체
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
WO2025024726A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinase
CN117756747A (zh) * 2023-12-21 2024-03-26 济宁医学院 一种n-苯基含氮多元环季铵盐类化合物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013128029A1 (en) * 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine derivatives
WO2013128028A1 (en) * 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CN100376580C (zh) * 2002-09-04 2008-03-26 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200536536A (en) * 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
JP2009007342A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
JP2010529140A (ja) * 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3805218A1 (en) 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3268000B1 (en) * 2015-03-09 2021-08-04 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
WO2019144149A2 (en) * 2018-01-22 2019-07-25 Fred Hutchinson Cancer Research Center Treatment methods for pancreatic tumors associated with the worst prognosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013128029A1 (en) * 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine derivatives
WO2013128028A1 (en) * 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors

Also Published As

Publication number Publication date
NZ768649A (en) 2024-10-25
WO2019197549A1 (en) 2019-10-17
IL277770B2 (en) 2024-01-01
AU2019250507A1 (en) 2020-10-22
MX2020010675A (es) 2020-10-28
KR20200141487A (ko) 2020-12-18
PH12020551639A1 (en) 2021-07-05
KR102966455B1 (ko) 2026-05-15
MY199647A (en) 2023-11-14
JP7772501B2 (ja) 2025-11-18
SG11202009724YA (en) 2020-10-29
IL277770B1 (en) 2023-09-01
US20210147427A1 (en) 2021-05-20
CN112313235A (zh) 2021-02-02
US11945822B2 (en) 2024-04-02
JP2023138858A (ja) 2023-10-02
JP2021521120A (ja) 2021-08-26
IL277770A (en) 2020-11-30
BR112020020768A2 (pt) 2021-01-19
CA3095880A1 (en) 2019-10-17
EP3774810A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
US11945822B2 (en) Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase
AU2019250504B2 (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
AU2019259653B2 (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
AU2019267008B2 (en) Tetracyclic heteroaryl compounds
CA2976741C (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
ES2773046T3 (es) Cianopirrolidinas como inhibidores de DUB para el tratamiento del cáncer
ES2929376T3 (es) Nuevos compuestos
AU2022343903B2 (en) Spirocyclic compounds
CN112566916B (zh) 作为pad4抑制剂的经取代的噻吩并吡咯
AU2012300248B2 (en) Compounds and compositions as c-kit kinase inhibitors
DK2753329T3 (en) 1,5-NAPHTHYRIDINE INGREDIENTS AS MILK INHIBITORS
US12606561B2 (en) Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors
CN105814043A (zh) 用作tnf活性调节剂的三唑并吡啶衍生物
AU2019271952A1 (en) Substituted benzazinones as antibacterial compounds
CA2765942A1 (en) Flavin derivatives
AU2022272181B9 (en) Compounds and uses thereof
US20240343732A1 (en) Compounds for degradation of cyclin-dependent kinase 7(cdk7)
RU2809779C2 (ru) Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы
KR20220136395A (ko) Irak4 억제제로서 유용한 트리시클릭 헤테로아릴 화합물
WO2015016195A1 (ja) Ｗｎｔシグナル阻害剤
RU2818563C2 (ru) Фармацевтически активные производные пиразолотриазина и/или пиразолопиримидина
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
WO2026039844A1 (en) Stat6 degraders and uses thereof
HK1256059B (en) An inhibitor of deubiquitylating enzymes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)